Actelion, Nippon Shinyaku sales and marketing update

In January, Actelion launched Uptravi selexipag in the U.S. to treat pulmonary arterial hypertension (PAH). The wholesale acquisition cost (WAC) is $9,340 for 60 oral tablets of the 200 ug dose; $21,...